Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2

Journal of Nanobiotechnology

Volumn 10, Issue , 2012, Pages

  Arora, Upasana ^a   Tyagi, Poornima ^a   Swaminathan, Sathyamangalam ^a   Khanna, Navin ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIONANOPARTICLES; COMPETITIVE ELISA; DENGUE VIRUS; E. COLI; ENVELOPE DOMAINS; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; PLATFORM TECHNOLOGY; POLYCLONAL ANTIBODY; POTENTIAL APPLICATIONS; STRUCTURAL PROTEINS; SYNTHETIC GENES; VACCINE DEVELOPMENT; VIRUS-LIKE PARTICLES;

AFFINITY CHROMATOGRAPHY; ANTIBODIES; ANTIGENS; ELECTRON MICROSCOPY; ESCHERICHIA COLI; GENE ENCODING; NANOPARTICLES; POLYPEPTIDES; VACCINES;

VIRUSES;

HEPATITIS B CORE ANTIGEN; NANOPARTICLE; POLYCLONAL ANTIBODY; POLYPEPTIDE; VIRUS ENVELOPE PROTEIN; DENGUE VACCINE; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

AFFINITY CHROMATOGRAPHY; ANTIBODY TITER; ARTICLE; DENGUE VIRUS 2; ELECTRON MICROSCOPY; ENVELOPE DOMAIN III; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE CONSTRUCT; IMMUNOFLUORESCENCE; IMMUNOGENICITY; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; DENGUE; DENGUE VIRUS; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; VACCINATION;

DENGUE VIRUS GROUP; DENGUE VIRUS TYPE 2; HEPATITIS B VIRUS;

ANIMALS; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE EXPRESSION; HEPATITIS B CORE ANTIGENS; HUMANS; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS;

EID: 84864607163     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-10-30     Document Type: Article

References (24)

1. World Health Organization Factsheet No117 Dengue and dengue haemorrhagic fever 2012, www.who.int/mediacentre/factsheets/fs117/en/[Accessed April 27, 2012], World Health Organization Factsheet No117.
2. Gubler DJ, Kuno G, Markoff L. Flaviviruses. Fields Virology 2007, 1153-1252. Wolters Kluwer and Lippincott Williams & Wilkins, Philadelphia, Knipe DM, Howley PM, 5.
3. Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Patents 2010, 20:819-835.
4. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011, 29:7276-7284. 10.1016/j.vaccine.2011.07.017, 21781998.
5. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillén G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010, 9:137-147. 10.1586/erv.09.139, 20109025.
6. Kuhn RJ, Zhang W, Rossman MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108:717-725. 10.1016/S0092-8674(02)00660-8, 11893341.
7. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007, 81:12816-12826. 10.1128/JVI.00432-07, 2169112, 17881453.
8. Crill WD, Roehrig RT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001, 75:7769-7773. 10.1128/JVI.75.16.7769-7773.2001, 115016, 11462053.
9. Yildiz I, Shukla S, Steinmetz NF. Applications of viral nanoparticles in medicine. Curr Opin Biotechnol 2011, 22:901-908. 10.1016/j.copbio.2011.04.020, 21592772.
10. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796. 10.1038/nri2868, 20948547.
11. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001, 44:98-114. 10.1159/000050037, 11509871.
12. Gregson AL, Oliveira G, Othoro C, Calvo-Calle JM, Thorton GB, Nardin ER, Edelman R. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One 2008, 3:e1556. 10.1371/journal.pone.0001556, 2216688, 18253503.
13. Fiers W, de Filette M, Bakkouri KE, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283. 10.1016/j.vaccine.2009.07.007, 19840661.
14. Kratz PA, Böttcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 1999, 96:1915-1920. 10.1073/pnas.96.5.1915, 26711, 10051569.
15. Wang XJ, Gu K, Xiong QY, Shen L, Cao RY, Li MH, Li TM, Wu J, Liu JJ. A novel virus-like particle-based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK. Vaccine 2009, 27:7377-7384. 10.1016/j.vaccine.2009.09.022, 19778518.
16. Skamel C, Ploss M, Böttcher B, Stehle T, Wallich R, Simon MM, Nassal M. Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody response against Borrelia burgdorferi infection. J Biol Chem 2006, 281:17474-17481. 10.1074/jbc.M513571200, 16621801.
17. Nassal M, Skamel C, Kratz PA, Wallich R, Stehle T, Simon MM. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur J Immunol 2005, 35:655-665. 10.1002/eji.200425449, 15668917.
18. Boulter NR, Glass EJ, Knight PA, Bell-Sakyi L, Brown CGD, Hall R. Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial. Vaccine 1995, 13:1152-1160. 10.1016/0264-410X(95)00026-W, 8578798.
19. Koletzki D, Biel SS, Meisel H, Nugel E, Gelderblom HR, Krüger DH, Ulrich R. HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Biol Chem 1999, 380:325-333.
20. Geldmacher A, Skrastina D, Petrovskis I, Borisova G, Berriman JA, Roseman AM, Crowther RA, Fischer J, Musema S, Gelderblom HR, Lundkvist A, Renhofa R, Ose V, Krüger DH, Pumpens P, Ulrich R. An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. Virology 2004, 323:108-119. 10.1016/j.virol.2004.02.022, 15165823.
21. Karpenko LI, Ivanisenko VA, Pika IA, Chikaev NA, Eroshkin AM, Veremeiko TA, Ilyichev AA. Insertion of foreign peptides in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000, 18:329-337. 10.1007/s007260070072, 10949916.
22. Batra G, Raut R, Dahiya S, Kamran N, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. J Virol Meth 2010, 167:10-16.
23. Korrapati AB, Swaminathan G, Singh A, Khanna N, Swaminathan S. Adenovirus Delivered Short Hairpin RNA Targeting a Conserved Site in the 5' Non-Translated Region Inhibits All Four Serotypes of Dengue Viruses. PLoS Negl Trop Dis 2012, in press.
24. Etemad B, Batra G, Raut R, Dahiya S, Khanam S, Swaminathan S, Khanna N. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Amer J Trop Med Hyg 2008, 79:353-363.